MDNA and MDNAF Related Headlines
Go Back- Medicenna raises CDN$4.44 million in public offering of units
- Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- Medicenna finalizes terms for public offering at $0.50 per unit
- Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
- Medicenna launches public offering to fund clinical programs
- Medicenna Announces the Launch of a Marketed Public Offering of Securities
- Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
- Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
- Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
- Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
- Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
- Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
- Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
- Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
- Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream
MDNA and MDNAF Related Press Releases
Go Back- Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
- Medicenna Announces the Launch of a Marketed Public Offering of Securities
- Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
- Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
- Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
- Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
- Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
- Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
- Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
- Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
- Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream
